Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of axitinib (AG-013736) in 131I-refractory metastatic or unresectable thyroid cancer
2006-002576-18Phase 2Completed
- Sponsor
- Pfizer
- Start
- Oct 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of axitinib in papillary thyroid cancer (PTC), follicular carcinoma (FTC), Hürthle cell carcinoma of the thyroid (HCC) and 2 more, sponsored by Pfizer. Started Oct 2006; status: completed.
02
Drugs
axitinib
03
Conditions
papillary thyroid cancer (PTC)follicular carcinoma (FTC)Hürthle cell carcinoma of the thyroid (HCC)Medullary Thyroid Cancer (MTC)thyroid cancer
Beyond the preview
Go deeper on 2006-002576-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002576-18.